Clinical trial · Interventional
Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma
Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAF Inhibitors/MEK Inhibitors (BRAFi/MEKi) in BRAF Mutated Melanoma
NCT04039672CI-TRIAL-00081494MELANOPREDICTcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an interventional mono-centric study in patients with BRAF mutated metastatic melanoma treated with BRAF/MEK inhibitors. The aim of the study is to test the grafting of patient tumoral cells in avian embryo and develop a predictive in vivo model for patient treatment response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Skin biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Biopsy
- description
- Skin biopsy before BRAFi/MEKi treatment
- interventionNames
- Procedure: Skin biopsy
Primary outcomes (2)
- measure
- Grafted avian embryo development
- timeFrame
- 2 days post graft
- description
- Number of grafted embryo which develop tumor measurable by 3D microscopy
- measure
- Grafted avian embryo viability
- timeFrame
- 2 days post graft
- description
- Survival rate of grafted embryo
Secondary outcomes (12)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged ≥ 18 years * Signed written informed consent * Patient with BRAF V600 mutated metastatic or unresectable melanoma histologically confirmed * BRAFi/MEKi treatment indication * Patient with skin tumor (excluded face and skinfold) available for biopsy * Measurable disease as defined by RECIST v1.1 criteria * Patient affiliated to or a beneficiary of a social security category Exclusion Criteria: * Ocular melanoma * Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study * Pregnant or nursing (lactating) women * Patients protected by law
References
Publications (0)
Data not yet available
No reference posted for this study.